Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide having SEQ ID NO:
- 1 in human patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one antisense oligonucleotide 16 to 26 nucleotides in length wherein said at least one oligonueleotide has at least 80% sequence identity to a reverse complement of a polynueleotide comprising 10 to 30 consecutive nucleotides within nucleotides 1 to 413 of SEQ ID NO;
2 and 1 to 413 of SEQ ID NO;
3;
thereby upregulating a function of and/or the expression of the Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide in patient cells or tissues in vivo or in vitro.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2.
-
Citations
16 Claims
-
1. A method of upregulating a function of and/or the expression of a Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide having SEQ ID NO:
- 1 in human patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one antisense oligonucleotide 16 to 26 nucleotides in length wherein said at least one oligonueleotide has at least 80% sequence identity to a reverse complement of a polynueleotide comprising 10 to 30 consecutive nucleotides within nucleotides 1 to 413 of SEQ ID NO;
2 and 1 to 413 of SEQ ID NO;
3;
thereby upregulating a function of and/or the expression of the Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide in patient cells or tissues in vivo or in vitro. - View Dependent Claims (12)
- 1 in human patient cells or tissues in vivo or in vitro comprising;
-
2. A method of upregulating a function of and/or the expression of a Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide having SEQ ID NO:
- 1 in human patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one antisense oligonucleotide 16 to 26 nucleotides in length wherein said at least one oligonucleotide is specific for a natural antisense polynucleotide of the TNFR2 polynucleotide and has at least 80% sequence identity to a 16 to 26 nucleotide region of as reverse complement of said natural antisense of a Tumor Necrosis Factor Receptor 2 (TNFR2) polynueleotide;
thereby upregulating a function of and/or the expression of the Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide in patient cells or tissues in vivo or in vitro.
- 1 in human patient cells or tissues in vivo or in vitro comprising;
-
3. A method of upregulating a function of and/or the expression of a Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide having SEQ ID NO:
- 1 in human patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one antisense oligonucleotide of 18 to 24 nucleotides in length that specifically targets a complementary region of a natural antisense oligonucleotide of the Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide;
thereby upregulating a function of and/or the expression of the Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide in patient cells or tissues in vivo or in vitro. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11)
- 1 in human patient cells or tissues in vivo or in vitro comprising;
-
13. A method of modulating a function of and/or the expression of a Tumor Necrosis Factor Receptor 2 (TNFR2) polyttucleotide having SEQ ID NO:
- 1 in human cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one short interferina, RNA (siRNA) oligonucleotide 19 to 26 nucleotides in length, said at least one siRNA oligonucleotide being specific for a natural antisense polynucleotide of a Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide, wherein said at least one siRNA oligonucleotide has at least 80% sequence identity to a complementary sequence of at least about 19 consecutive nucleic acids of the sense nucleic acid molecule of the Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide; and
, upregulating a function of and/or the expression of Tumor Necrosis Factor Receptor 2 (TNFR2) in mammalian cells or tissues in vivo or in vitro. - View Dependent Claims (14)
- 1 in human cells or tissues in vivo or in vitro comprising;
-
15. A method of upregulating a function of and/or the expression of Tumor Necrosis Factor Receptor 2 (TNFR2) in mammalian cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one antisense oligonucleotide of about 10 to 30 nucleotides in length specific for noncoding and/or coding sequences of a natural antisense strand of a Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide wherein said at least one antisense oligonucleotide has at least 50% sequence identity to at least one nucleic acid sequence of about 10 to 30 nucleotides in length set forth within SEQ ID NO;
1 or a polynucleotide encoded by the TNFR2 gene; and
, upregulating the function and/or expression of the Tumor Necrosis Factor Receptor 2 (TNFR2) in mammalian cells or tissues in vivo or in vitro.
-
16. A method of preventing or treating, a disease or condition associated with at least one Tumor Necrosis Factor Receptor 2 (INFR2) polynucleotide having SEQ ID NO:
- 1, comprising;
administering to a human patient a therapeutically effective dose of at least one modified antisense oligonucleotide of 16 to 26 nucleotides in length that binds to a natural antisense sequence of said at least one Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide and upregulates expression of said at least one Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide;
thereby preventing or treating the disease associated with the at least one Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide and/or at least one encoded product thereof Wherein said disease or condition is selected from inflammation or rheumatoid arthritis or an autoimmune disease or disorder or Crohn'"'"'s disease or ischemia.
- 1, comprising;
Specification